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In Response:
We thank Dr. Sabour for his com-
ments and the opportunity to clarify a 
number of points from our study.1
The use of (weighted) κ is cur-
rently the standard method of report-
ing and as such there should not be 
any controversy. The limitations of κ 
statistics in relation to prevalence and 
number of categories are well known, 
including the provided example in 
Figure 1.2 However, we take issue with 
his statement “As the authors point out 
in their conclusion, the histologic crite-
ria that may be used in the differential 
diagnosis of poorly differentiated lung 
cancer were more precisely refined. 
Such conclusion, due to inappropriate 
use of statistical test can be mislead-
ing. Misdiagnosis and mismanagement 
of the patients in routine clinical care 
cannot be avoided using inappropri-
ate tests to assess reliability. As a take 
home message, for reliability analysis, 
appropriate tests should be applied by 
researchers. Otherwise, misdiagnosis 
and mismanagement of the patients 
cannot be avoided.”
First of all, in our article,1 the 
cited κ scores for categories large cell, 
basaloid, sarcomatoid carcinoma, lym-
phoepithelial-like, and solid adenocar-
cinoma ranging from 0.21 to 0.56 were 
calculated over two classes (specific 
diagnosis versus other). Thus, one of 
the two above-mentioned limitations of 
the κ scores, lower κ values when using 
more categories, is not applicable. In 
addition, the article states that each of 
the cited κ values represents the mean 
value of 120 comparisons (16 observ-
ers; [16 × 15] of 2 combinations) for 
each diagnostic category, which is a 
high enough number to exclude large 
variations due to possible differences 
in prevalence, as is also shown by the 
95% confidence intervals in Table 5.1 
Therefore, the κ outcome measures in 
our study are based on sound applica-
tion of κ statistics, not inappropriately 
used. In addition, the obtained κ values 
are, where available, in line with the 
literature.3–5
The manuscript also states that 
definitions of criteria used were refined 
in the pilot study mentioned in the mate-
rials and methods section, before the 
part where κ scoring was performed.
As for the content: the primary 
objective of our study was to assess 
the value of immunohistochemistry in 
improving diagnosis of poorly differen-
tiated non–small-cell lung carcinoma 
(NSCLC) as participating pathologists 
are aware of limited information present 
in routine hematoxylin and eosin sec-
tions. This led to low κ scores in poorly 
differentiated NSCLC, and therefore 
the participating pathologists advo-
cated the use of additional stains when 
specific criteria were lacking, result-
ing in increased κ values for several 
categories (again based on 120 com-
parisons). As a take-home message we 
formulated: “Furthermore, additional 
stains improved the reproducibility of 
histological diagnosis of squamous 
cell carcinoma and adenocarcinoma, 
uncovering information that was not 
present in routine hematoxylin and 
eosin-stained slides.” We believe that 
our conclusion is based on appropriate 
use of κ statistics that supports the use 
immunohistochemistry in the diagnosis 
of poorly differentiated NSCLC, lead-
ing to better management of patients in 
routine clinical care.
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